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Vascular sclerosis is often seen in renal biopsies. It is usually
associated with diabetes mellitus, hypertension, smoking,
etc. However, whether inherited thrombophilic states such as
factor V gene mutation, prothrombin gene mutation, and
methylenetetrahydrofolate reductase (MTHFR) gene
mutation are associated with the vascular sclerosis is not
known. Renal biopsies that showed vascular disease were
grouped into five groups: (1) diabetic patients, (2)
hypertensive patients, (3) diabetic and hypertensive patients,
(4) smokers, and (5) vascular sclerosis of unknown etiology
(idiopathic renal disease). Renal biopsies with no vascular
sclerosis were used as controls. Frozen tissue was analyzed
for factor V Leiden mutation, prothrombin G20210A
mutation, and MTHFR C677T. Factor V Leiden mutation and
prothrombin G20210A mutation was not seen in patients
with diabetes, hypertension, or smoking, whereas MTHFR
C677T polymorphism in these groups was not significant,
compared to the controls. In the idiopathic renal disease
group, three of the 17 patients (17.6%) had prothrombin
G20210A mutation, two of the 17 patients (11.8%) had the
factor V Leiden mutation, and five of the 17 (29.4%) were
homozygous for the MTHFR C677T polymorphism. When the
data were evaluated as a whole, 10 mutations were found in
17 patients (Po0.0005 compared to controls) or eight of the
17 patients (47%) were observed to have at least one of the
three forms of inherited thrombophilia (Po0.001 compared
to controls). These findings indicate that renal vascular
lesions, in the absence of diabetes, hypertension, or smoking
appears to be associated with inherited thrombophilias.
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An acquired or inherited predisposition to thrombosis is
referred to as thrombophilia.1 Thrombophilia is a hyper-
coagulable state that shifts the balance between procoagulant
and anticoagulant forces in favor of coagulation.2–5 Inherited
thrombophilia assumes the presence of a genetic factor that
predisposes an individual towards thrombosis, but requires
additional prothrombotic triggers before onset of a clinical
disorder occurs. Initially, thrombophilic genetic defects were
found within coding regions of genes. It is now known that
polymorphisms in regulatory regions of coagulation plasma
factor genes also have an important impact because of their
effect on the synthesis rate and concentration of the protein.6,7
To date, several gene polymorphisms have been investi-
gated in thrombophilia, including factor V gene mutation,
prothrombin gene mutation, methylenetetrahydrofolate
reductase (MTHFR) gene mutation, plasminogen activator-1
mutations, factor H mutation, deficiencies in Antithrombin,
Protein C and S, etc. Factor V Leiden is considered the most
commonly known genetic defect associated with venous
thromboembolism. Hypercoagulability occurs in patients with
factor V Leiden owing to a stabilization of the prothrombinase
complex, which enables continued thrombin generation.
Prothrombin gene mutation is associated with an approxi-
mately 25% increase in plasma thrombin activity, due to
increase in post-translational 30 end processing efficiency,
leading to a higher transcription rate of prothrombin.
Prothrombin G20210A is now considered one of the most
prevalent genetic abnormalities linked to thrombophilia,
second only to factor V Leiden. Elevated levels of homo-
cysteine are associated with increased risk of thrombosis. The
most common genetic factors involved in hyperhomocystein-
emia include mutant forms of MTHFR resulting in its reduced
specific activity and increased thermolability. A variant of
MTFHR called MTFHR C677T (due to C to T substitution at
bp 677) results in reduced activity at 371C and increased
thermolability at 461C.8–14 Whereas factor V Leiden and
Prothrombin G20210A mutation are most commonly asso-
ciated with venous thromboembolism, hyperhomocystein-
emia is linked to both arterial and venous thrombosis.15–17
Thrombophilia in renal disease
We designed an association study to assess the importance
of inherited thrombophilia, specifically factor V Leiden,
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prothrombin G20210A, and MTHFR C677T, with biopsy-
proven renal vascular disease in patients with and without
other risk factors for vascular disease.
RESULTS
Vascular injury
Figure 1 shows the typical lesions seen in any of the groups
including the idiopathic renal vascular disease group,
although the severity and extent of vascular sclerosis was
quite variable. Arteries and arterioles showed sclerosis of the
intima and media, and moderate hypertrophy of the media.
Electron microscopy often showed evidence of glomerular
capillary wall remodeling with short segments of double
contouring owing to cellular interposition and new glome-
rular basement formation. In the idiopathic vascular disease
group (Table 1), the extent of vascular sclerosis varied from
1þ to 4þ (average 2.3, s.e.m.70.20). The severity of
vascular sclerosis did not correlate with the presence of an
inherited thrombophilic state. In addition, double contours
were noted in only some cases in the idiopathic group.
Additional biopsy findings in the idiopathic group included
secondary focal segmental and global glomerulosclerosis in
four cases and focal global glomerulosclerosis in two cases
out of 17 cases, and mild to moderate tubular atrophy and
interstitial fibrosis. In the idiopathic group, most patients
presented with modest rise in serum creatinine (average
1.82 mg/dl, range: 0.8–3.9 mg/dL, s.e.m.70.24). Urinalysis
showed proteinuria in 13 out of 17 cases and hematuria in
seven out of 17 cases. The 24 h urinary protein analysis was
carried out in nine cases (average 1.4 gms/24 h, s.e.m.70.4).
Results of factor V, prothrombin, and MTHFR genotypes
Control group. In this study, a control group was formed
using renal biopsies from patients that did not show evidence
of renal vascular disease. The genotype was determined for
the prothrombin gene, factor V gene, and the MTHFR gene
for 25 control patients (Table 2). Within this group, none of
the patients tested had either the prothrombin G20210A
allele or the factor V Leiden allele. Additionally, this control
group only had one patient homozygous for the MTHFR
Figure 1 | Typical vascular lesion. (a) PAS-stained section showing
an artery with intimal sclerosis, myointimal hyperplasia, and
thickening of the wall. (b) Electron microscopy showing
subendothelial expansion with cellular elements and new
glomerular basement formation in the absence of electron
dense deposits, resulting in double contours (arrows) (original
magnification  1850).
Table 1 | Clinical and pathologic features of idiopathic renal vascular disease group
Patient PT FV MTHFR
Age/
sex
Arterial and
arteriolar
sclerosis
Serum
creatinine Urine analysis Additional biopsy findings
1 G/G G/G C/C 50/F + Unknown Unknown Glomerular capillary wall remodeling
2 G/G G/G C/C 34/F + to ++ Normal Hematuria, Urinary protein:
1 g/24 h
Focal and segmental
glomerulosclerosis, secondary
3 G/A G/G C/T 68/M +++ Unknown Urinary protein: 4 g/24 h Minimal change disease
4 G/G G/G C/T 43/M +++ 1.4 mg/dl Urinary protein: 1 g/24 h Focal global glomerulosclerosis
5 G/A G/G C/C 55/M ++ 1.0 mg/dl Trace blood urinary protein:
446 mg/24 h
—
6 G/A G/G C/C 56/F +++ 1.3 mg/dl Hematuria, creatinine clearance
56 ml/min
Focal and global glomerulosclerosis,
thin glomerular basement membranes
7 G/G G/G C/T 49/M +++ 1.6 mg/dl Urinary protein: 2.5 g/24 h —
8 G/G G/G T/T 52/M + 1.4 mg/dl Urinary protein: 2.0 g/24 h Focal segmental and global
glomerulosclerosis, secondary
9 G/G G/G C/C 59/F ++ 1.8 mg/dl Hematuria and proteinuria Glomerular capillary wall remodeling
10 G/G G/G T/T 54/F +++ Unknown Proteinuria Focal segmental and global
glomerulosclerosis, secondary
11 G/G G/G C/T 60/M ++ Normal Urinary protein: 1.0 g/24 h —
12 G/G G/G T/T 63/F +++ 2.5 mg/dl Proteinuria 2+ Acute tubular necrosis
13 G/G G/G C/T 73/M +++ to ++++ 3.9 mg/dl Hematuria —
14 G/G G/A T/T 59/F + 1.7 mg/dl Urinary protein: 0.4 g/24 h Focal global glomerulosclerosis
15 G/G G/G C/C 73/F +++ 2.3 mg/dl Trace blood Focal segmental and global
glomerulosclerosis, secondary
16 G/G G/G C/C 66/F ++ to +++ 1.2 mg/dl Urinary protein: 400 mg/24 h
hematuria
17 G/G G/A T/T 39/M + Unknown Proteinuria
F, female; FV, Factor V Leiden; M, Male; MTHFR, methylenetetrahydrofolate reductase; PT, prothrombin.
Patient characteristics of idiopathic renal vascular disease group: G/G represents wild-type Factor V and Prothrombin genes, whereas G/A represents prothrombin mutation
and Factor V Leiden mutation. T/T represents homozygous MTHFR C677T mutation, wheeras C/T represents the heterozygous state.
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C677T mutation. Each of the following experimental group
was compared to these findings using Fischer’s exact test.
Diabetes and hypertension
1. Upon examination of the diabetes alone patients, we
found that none of these patients possessed either the
prothrombin G20210A mutation (Table 2a) or the factor
V Leiden mutation (Table 2b), whereas one out of
six patients was homozygous for the MTHFR C677T
polymorphism (16.7%) (Table 2c). As no G20210A
mutation or factor V Leiden mutation was found, the
Fischer’s exact test could not be determined between the
controls and this group, and it appears that there is no
significant difference between these groups with respect
to prothrombin G20210A and factor V Leiden preva-
lence. Fisher’s exact test was performed to compare the
incidence of MTHFR C677T in these patient popula-
tions, but no significant difference was determined
(P¼ 0.355, Power¼ 0.1692).
2. Of the 15 patients examined with hypertension alone,
none of them possessed either the prothrombin
G20210A mutation (Table 2a) or the factor V Leiden
mutation (Table 2b) and only one was homozygous for
the MTHFR C677T mutation (Table 2c). Similar to the
diabetes alone data, the Fisher’s exact test could not
be performed to determine the significance of the
prothrombin G20210A mutation and the factor V Leiden
mutation in this patient group compared to the control
group because neither possessed either of these muta-
tions. Therefore, it appears that there is no significant
difference between these groups with respect to pro-
thrombin G20210A and factor V Leiden prevalence. The
hypertension alone patient population had one patient
homozygous for the MTHFR C677T polymorphism
Table 2 | Prevalence of inherited thrombophilic factors in each experimental population compared to the control population
(a) Incidence of prothrombin G20210A
Group Total Mutant PT PT (%) P-value Relative risk 95% CI
Diabetes 6 0 0.0 1.000 N/A N/A
Hypertension 15 0 0.0 1.000 N/A N/A
Diabetes/hypertension 13 0 0.0 1.000 N/A N/A
D/H overall 34 0 0 1.000 N/A N/A
Smokers 8 0 0.0 1.000 N/A N/A
Idiopathic 17 3 17.6 0.059 5.1 1.8–4.2
Control 25 0 0.0 N/A N/A N/A
(b) Incidence of factor V Leiden
Group Total Mutant FV FV (%) P-value Relative risk 95% CI
Diabetes 6 0 0.0 1.000 N/A N/A
Hypertension 15 0 0.0 1.000 N/A N/A
Diabetes/hypertension 13 0 0.0 1.000 N/A N/A
D/H overall 34 0 0 1.000 N/A N/A
Smokers 8 0 0.0 1.000 N/A N/A
Idiopathic 17 2 11.8 0.158 N/A N/A
Control 25 0 0.0 N/A N/A N/A
(c) Incidence of homozygosity for MTHFR C677T
Group Total Mutant MTHFR MTHFR % P-value Relative risk 95% CI
Diabetes 6 1 16.7 0.355 N/A N/A
Hypertension 15 1 6.7 0.615 N/A N/A
Diabetes/hypertension 13 2 15.4 0.265 N/A N/A
D/H overall 34 4 11.8 0.287 N/A N/A
Smokers 8 2 25.0 0.139 N/A N/A
Idiopathic 17 5 29.4 0.032 2.5 1.4–4.5
Control 25 1 4.0 N/A N/A N/A
(d) Incidence of having at least one mutation (prothrombin G20210A, factor V Leiden, or MTHFR C677T)
Group Total Total Mut. Total Mut. (%) P-value Relative risk 95% CI
Diabetes 6 1 16.7 0.355 N/A N/A
Hypertension 15 1 6.7 0.615 N/A N/A
Diabetes/hypertension 13 2 15.4 0.265 N/A N/A
D/H overall 34 4 11.8 0.287 N/A N/A
Smokers 8 2 25.0 0.139 N/A N/A
Idiopathic 17 10 58.8 0.0005 4 2.0–7.9
Control 25 1 4.0 N/A N/A N/A
CI, confidence interval; D/H, diabetes/hypertension; FV, Factor V Leiden; MTHFR, methylenetetrahydrofolate reductase; PT, prothrombin.
Significant findings are given in bold.
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(6.7%), again no significant difference was observed
compared to the control group (P¼ 0.615, Power¼
0.0648).
3. The diabetes and hypertension patients had similar
results to the diabetes alone patients and the hyperten-
sion alone patients. We found that none of them had
either the prothrombin G20210A gene or the factor V
Leiden gene. The prevalence of patients homozygous
for MTHFR C677T (15.4%) was compared to the control
group as was the prevalence of the mutations as a whole.
The diabetes and hypertension patients were not found
to be significantly different from the controls with
respect to MTHFR C677T or the mutations as a whole
(P¼ 0.265, Power¼ 0.136).
As these two diseases can be associated in many ways, they
were combined into one group (i.e.: all cases of diabetes
alone, hypertension alone, and diabetes and hypertension),
which will be referred to as diabetes and hypertension. This
group, containing 34 patients, had no prothrombin G20210A
gene or the factor V Leiden gene. Thus, there is no significant
difference between prothrombin G20210A and factor V
Leiden prevalence in diabetes and hypertension patients as
a whole compared to control subjects. Four patients in the
diabetes and hypertension group were homozygous for
the MTHFR C677T mutation (11.8%). When compared to
the control data with the Fischer’s exact test, this combined
group showed no significant difference with respect to
MTHFR C677T or to the three mutations as a whole
(P¼ 0.287, Power¼ 0.0717).
Smokers
None of the eight patients in the smoking group had either
the prothrombin G20210A mutation or the factor V Leiden
mutation. Two of the eight patients in the smoking group
(25%) were homozygous for the MTHFR C677T mutation.
The Fischer’s exact test comparison of the incidence of
MTHFR C677T in smokers relative to controls did not
demonstrate a significant difference between these groups
(P¼ 0.139, Power¼ 0.2727).
Idiopathic renal vascular disease cases
The idiopathic renal disease group, which was examined next,
illustrates a patient population that has never previously been
examined with respect to inherited thrombophilia. This
group consisted of patients with renal vascular disease on
biopsy, but with no underlying medical conditions such as
diabetes, hypertension, immune complex disease, drug use,
or other predisposing factors for vascular disease in the
kidney. We hypothesized that this group with seemingly
idiopathic renal vascular disease may have been predisposed
to vascular scarring by thrombophilic gene mutations.
Of the 17 biopsies collected from patients with idiopathic
renal disease (Table 2), three patients (17.6%) were found
to have the prothrombin G20210A mutation (P¼ 0.059,
Power¼ 0.3077) and a relative risk of 2.8 (95% confidence
interval, 1.8–4.2). Two patients (11.8%) were found to
be factor V Leiden carriers (P¼ 0.158, Power¼ 0.1671).
The MTHFR C677T polymorphism was found in five of
the patients in this group (29.4%). The MTHFR C677T
polymorphism was determined to be significantly increased
compared to the control group (P¼ 0.032; Power¼ 0.4654)
with a conferred relative risk of 2.5 (95% confidence interval,
1.4–4.5). Additionally, when the patients with one or more
mutations are looked at as a whole, eight out of the 17 (47%)
patients had at least one of these forms of inherited
thrombophilia. This was a significant finding of the Fisher’s
exact test when compared to the control group (Po0.001;
Power¼ 0.84). From these data, we calculated a relative risk
of 3.3 (95% confidence interval, 1.8–6.0). When looked as
a number of mutations, 10 mutations were found in 17
patients (58.8%) (Po0.0005, Power¼ 0.965). From these
data, we calculated a relative risk of 4.0 (95% confidence
interval, 2.0–7.9).
Power analyses
The sample size of controls (n¼ 25) and the idiopathic group
(n¼ 17) would provide 80% power to detect a difference in
the proportion with a mutation of 4% in controls and 43% in
the idiopathic group. For the diabetes and hypertension cases
(n¼ 34), there would be 80% power to detect a difference of
4% in controls and 34% in the diabetes and hypertension
group, and for the smoking group (n¼ 8), there would
be 80% power to detect a difference of a proportion of 4% in
controls and 57% in the smoking group.
DISCUSSION
In this study, the incidence of three genetic mutations
(prothrombin G20210A, factor V Leiden, and MTHFR
C677T) for inherited thrombophilia was evaluated in patients
with biopsy-proven renal vascular disease. The purpose of this
association study was to determine if there is an association
between renal vascular disease and inherited thrombophilia.
We propose that patients with inherited thrombophilia
experience small, chronic thrombotic events within the renal
vasculature, which is followed by repair that leads to vascular
scarring and glomerular capillary wall remodeling that result
in gradual and progressive decline in renal function.
This hypothesis was examined using a select experimental
population. The chronic, slow-progressing nature of the
proposed disease process was addressed by selecting patients
that were 30 years of age or older at the time of biopsy. Our
study included five groups of patients that showed vascular
lesions on biopsy: patients with (1) diabetes mellitus, (2)
hypertension, (3) diabetes and hypertension, (4) smokers,
and (5) idiopathic renal vascular group. The frequencies of
factor V Leiden, prothrombin G20210A, and MTHFR C677T
were evaluated in each of the renal vascular disease
populations and compared to a control population (Table 2).
For controls, we used renal biopsy tissue that did not show
vascular sclerosis, but had other forms of renal disease,
including primary glomerulonephritis. As the frequency of
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thrombophilic states can vary depending upon region and
race and in order to remove any bias, our controls consisted
of the same population pool from which cases were derived
for groups 1 through 5.
In 34 patients with diabetes, hypertension, or both, none
possessed the prothrombin G20210A mutation or the factor
V Leiden mutation. Four of the 34 patients in this group were
homozygous for the MTHFR C677T polymorphism, but this
was not a significant difference compared to the controls.
These data appear to indicate that vascular lesions seen in
patients with diabetes and/or hypertension develop owing to
different underlying pathogenic mechanisms and that the
three mutations studied are not associated with the vascular
lesions seen in diabetes and/or hypertension. These are novel
findings with respect to the prothrombin and factor V
mutations. MTHFR, however, has been evaluated previously
as a risk factor for progression of diabetes and found to have
such an association.18–20 On the other hand, a recent study
found no association between homocysteine and arterio-
sclerotic outcomes in diabetic patients.21
The smoking patient population used in this study was
unique in that these patients gave history of many years of
smoking but did not have hypertension or diabetes (when
smoking was associated with hypertension, the patients were
excluded from the study). As the criteria for this group was
specific, the number of qualified patient samples was limited
to eight. Of the eight samples examined, none had either the
prothrombin G20210A mutation or the factor V Leiden
mutation, whereas two of the eight were homozygous for the
MTHFR C677T polymorphism, which is 25% of this
population; these findings were not significant compared to
the control group.
In the idiopathic vascular disease group, three of the 17
patients were found to have the prothrombin G20210A
mutation, two patients of the 17 had the factor V Leiden
mutation, and five of the 17 patients were homozygous for
the MTHFR C677T polymorphism. When the data was
evaluated as a whole, eight of the 17 patients (47%) were
observed to have at least one of the three forms of inherited
thrombophilia. Two patients had both factor V Leiden
mutation and were homozygous for the MTHFR C677T
polymorphism; a total of 10 mutations were seen in 17
patients. Thus, inherited thrombophilia occurred in almost
half the patients with idiopathic renal vascular disease and
these findings were significant compared to the controls. The
difference is also significant compared to the frequency of
these mutations seen in the general population (prothrombin
G20210A mutation in the general population is 1–2%, factor
V Leiden is 4–7%, and MTHFR C677T is 11–15%).
Although this study presents evidence that the prothrom-
bin G20210A mutation, the factor V Leiden mutation, and
homozygosity for the MTHFR C677T polymorphism play a
role in the development of renal vascular disease in patients
with idiopathic renal disease patients, there were some
underlying limitations that should be addressed. One of the
most confounding problems in this study was the small
patient populations. This occurred because only a limited
number of patient samples that conformed to the strict
criteria set by the study could be found during the time the
study was performed.
The frequency of the prothrombin G20210A mutation in
the general population is 1–2% (can vary depending on race).
A control population would therefore need to be near 100
subjects to find at least one prothrombin G20210A carrier, to
confirm that this group is representative of a standard
population. No prothrombin G20210A carriers in the control
population were observed because this population of 25
was too small to find a mutation with such a low general
population frequency. The same is true for the factor V
Leiden mutation, which has a frequency of 4–7% in the
general population (can vary depending on race). Without
any reported carriers of these two mutations in the control
population, many comparative statistical analyses could not
be performed. The frequency of homozygosity for MTHFR
C677T in the general population is much higher than the
previously mentioned mutations, 11–15%. However, the
frequency of homozygosity for MTHFR C677T was only
4% in our control population, which maybe due to the small
sample number.
Whereas increase in the frequencies of the mutations in
the idiopathic renal disease group yielded a significant
difference in light of their small numbers, other groups
showed no significant difference even when the percentage
difference between the experimental group and the control
group appeared quite high. For example, 11.8% of the
diabetes and hypertension group were homozygous for
the MTHFR C677T polymorphism, whereas only 4% of the
control group had this same mutation. At first glance,
this appears to be a substantial difference, but due to small
sample size, it is not statistically significant. The same was
true for the idiopathic renal disease cases with respect to the
factor V Leiden mutation, which showed the mutation in
11.8% of idiopathic group. The control frequency for these
mutations was 0%, but again sample size was limiting and no
significant difference could be shown.
This appears to be an excellent starting point for future
studies on thrombophilia and renal vascular disease. Whereas
thrombophilia has been studied in relation to many disease
pathologies, it is relatively unexplored in the context of renal
disease. Future studies should evaluate much larger control
and experimental populations. Because tissue, but not serum
for the patients was available, we looked exclusively at
inherited thrombophilic traits. However, subsequent studies
could involve other inherited forms such as mutations in
factor H and plasminogen activator-1 or acquired forms of
thrombophilia such as deficiencies of protein C, protein S or
antithrombin III, or the presence of anticardiolipin antibodies.
MATERIALS AND METHODS
Patients
Between January 2003 and February 2005, renal biopsies from 66
patients that demonstrated renal vascular disease were evaluated.
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Vascular sclerosis was defined by fibrous thickening of the intima,
and to a certain extent of the media, along with hypertrophy of the
media. These biopsies were cases sent to University of Iowa
Hospitals and Clinics for renal biopsy interpretation and diagnosis.
None of these cases had any evidence of immune complex-mediated
glomerulonephritis. In addition, 25 control age-matched patients
were selected for the study. An Institutional Review Board at the
University of Iowa approved the use of these biopsies on the basis
that the personal information of each patient would remain
unknown.
Study groups
Study and control patient populations were chosen on the basis of
age (430 years old) and medical history (see following categories).
Following the evaluation of the renal biopsies, which yielded
patients with renal vascular disease, a careful review of the patients
medical histories were performed. When vascular sclerosis was
noted in the renal biopsy, it was grouped into the following groups:
(1) diabetic patients, (2) hypertensive patients, (3) diabetic and
hypertensive patients, (4) patients who smoked, and (5) vascular
sclerosis of unknown etiology (idiopathic renal disease) patients.
Biopsies that showed vascular sclerosis but with other contributing
factors that may result in vascular sclerosis such as obesity,
medications such as nonsteroidal anti-inflammatory drugs, meta-
bolic diseases such as gout, etc. were excluded from the study.
Transplant biopsies were not included in the study. Biopsies that
showed immune complex disease were also not included in the
study. In group 4, patients had a history of smoking, but did not
have either diabetes or hypertension. Group five (idiopathic vascular
disease) was the only patient population without known contribut-
ing factors. The control group differed from the other five groups in
that these patients did not have evidence of vascular sclerosis in the
renal biopsy. The control cases included a random age-matched
sampling of renal cases that included immune complex-mediated
glomerulonephritides such as immunoglobulin A nephropathy,
lupus nephritis, membranous glomerulonephritis, membranoproli-
fertive glomerulonephritis; pauci-immune crescentic glomerulone-
phritis, interstitial nephritis, etc. The control cases were chosen from
the same patient population pool from which cases were used for
the other groups.
Renal biopsy
Histopathological evaluation was performed using light, immuno-
fluorescence, and electron microscopy.22 Stains used for light
microscopy included hematoxylin–eosin, Masson trichrome, peri-
odic acid-Schiff, and silver methenamine. The severity of the
vascular lesions was determined using a zero to four plus scale. Zero
represents normal or no lesions, one plus (þ ) indicates mild change
(vascular narrowing of up to 25% of luminal area by fibrointimal
thickening), two pluses (þ þ ) indicates moderate change (vascular
narrowing of up to 50% of luminal area by fibrointimal thickening),
three pluses (þ þ þ ) indicates moderately severe change (vascular
narrowing of up to75% of luminal area by fibrointimal thickening),
and four pluses (þ þ þ þ ) indicates severe lesions are present
(vascular narrowing of greater than 75% of luminal area by
fibrointimal thickening). The most severely affected vessels were
graded. Immunofluorescence microscopy using standard antibodies
(immunoglobulin G, immunoglobulin M, immunoglobulin A, C3,
albumin, fibrinogen, kappa and lambda light chains) was carried out
in all cases. None of the cases included in the study (except the
control cases) showed any evidence of immune complex-mediated
glomerulonephritis. Electron Microscopy was performed to study
the glomerular capillary wall and determine whether there was
evidence of endothelial cell injury and capillary wall remodeling
(double contours in the absence of electron dense deposits). Figure 1
shows typical vascular lesions on light microscopy and double
contours on electron microscopy. Cases were included in the study
in all the groups based on vascular sclerosis noted on light
microscopy, and not on the presence of double contours on electron
microscopy.
Genomic DNA extraction
Eligible samples, which were frozen in optimum cutting temperature
medium, were sectioned using a cryostat. The tissue was cut into
30 mm sections and three to five of these sections were used for DNA
extraction. Next, 500 ml of Hanks’ salt buffer solution was used to
solubilize the optimum cutting temperature. Following a 2-min spin
on maximum speed in a microcentrifuge, the optimum cutting
temperature-Hanks’ solution was drawn off of the renal tissue. The
samples were placed in a heating block at 801C with their lids open
for 5–10 min to dry them. To extract the DNA from the renal tissue,
100–200ml of proteinase K digestion buffer (50 mM Tris, 1 mM
ethylenediaminetetraacetate, and 0.5% Tween 20 with 200mg of
proteinase K per ml) was added to each dry sample. The samples
were then incubated for approximately 3 h at 561C or at 371C
overnight. Following this incubation, the samples were centrifuged
for 30 s to remove any condensed liquid from the cap, followed by
incubation at 951C for 8–10 min. Finally, the extracted genomic
DNA from each renal biopsy was cleaned-up using a Qiagen
QIAamp DNA Mini kit.
Diagnostic ASA-PCR
Allele-specific amplification polymerase chain reaction (ASA-PCR)
was used to determine the factor V, prothrombin, and MTHFR
genotypes of each patient. Whereas PCR restriction fragment length
polymorphism was the first technique used to identify these
mutations, ASA-PCR was used in this study because it takes less
time and has the same specificity as PCR restriction fragment length
polymorphism.23 Whereas PCR restriction fragment length poly-
morphism requires restriction digestion following PCR amplifica-
tion to determine genotype, ASA-PCR can identify genotype in just
one step. In ASA-PCR, two PCR reactions are carried out using an
allele-specific primer differing by the 30-OH extremity correspond-
ing to the nucleotide either specific for the mutant allele or specific
for the wild-type allele. In this study, factor V and prothrombin were
identified in one ASA-PCR reaction, whereas MTHFR was identified
using a separate ASA-PCR reaction.23–25 In these studies, an internal
control was used to validate the negative results. The ASA-PCR
control was the gene for factor IX.26 Positive controls for the
prothrombin G20210A gene and the factor V Leiden gene were also
used.
Primers
Factor V23 wild type: 50-GCA GAT CCC TGG ACA GAC G-30,
mutant: 50-GCA GAT CCC TGG ACA GAC A-30, common: 50-GGA
CTA CTT GAC AAT TAC TGT TCT CTT G-30; Prothrombin24 wild
type: 50-GCA CTG GGA GCA TTG AGG ATC-30, mutant: 50-GCA
CTG GGA GCA TTG AGG ATT-30, common: 50-TCT AGA AAC
AGT TGC CTG GCA G-30; MTHFR25 wild type: 50-AAG GAG AAG
GTG TCT GCG GGC GC-30, mutant: 50-AAG GAG AAG GTG TCT
GCG GGC GT-30, common: 50-AAG ATC CCG GGG ACG ATG
GGG-30;
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Factor IX control25 50-CTC CTG CAG CAT TGA GGG AGA TGG
ACA TT-30 50-CTC GAA TTC GGC AAG CAT ACT CAA TGT AT-30.
Each primer was resuspended in sterile water to a final concentra-
tion of 100mM.
Reaction
In total, 50 ml total reaction (5ml of 10 PCR Buffer: 1 PCR
Buffer (Applied Biosystems, Foster City, CA, USA), 6 ml of 25 mM
MgCl2: 3 mM MgCl2 (Applied Biosystems, Foster City, CA, USA),
1 ml of each 10 mM deoxynucleoside triphosphate: 200 mmol/l of each
deoxynucleoside triphosphate (Applied Biosystems, Foster City, CA,
USA), 2.5 ml of each 100 mM primer: 500 nmol/l of each primer
(Integrated DNA Technologies, Coralville, IA, USA), 5 ml of 25 ng/ml
DNA: 100 ng DNA, 0.5 ml of 5 U/ml Taq polymerase: 2.5 U of Taq
polymerase (Amplitaq Gold, Perkin-Elmer Cetus, Norfolk, CT,
USA) was amplified in a thermocylcer.
Diagnostic agarose gel electrophoresis
The amplified products were electrophoresed in a 2% agarose gel
run in 1 Tris Borate ethylenediaminetetraacetate (EDTA) (89 mM
Tris, 89 mM borate, and 2 mM ethylenediaminetetraacetate). Each gel
was stained with ethidium bromide and visualized under ultraviolet
(UV) light. Amplification resulted in the following final products:
340 bp (prothrombin), 250 bp (factor IX control), 174 bp (factor V),
and 127 bp MTHFR. Figure 2 illustrates how these products look on
their respective gels.
Statistical analysis
Results for each group compared to the control group were analyzed
with a two-tailed Fischer’s exact test. Statistical analyses were
performed with the Statistical Package for the Social Sciences for
Windows, version 12.0 (SPSS, Chicago, IL, USA). This software was
used to generate a P-value for each comparison, and P-values of 0.05
or less were considered significant. Relative risk, which is a measure
of how much a particular risk factor influences the risk of a specific
event or outcome, was also assessed for each patient group.27 Power
(P), which is a test for the probability that the test will reject the
hypothesis tested when a specific alternative hypothesis is true, was
also determined for each comparison.
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Figure 2 | Identification of prothrombin, factor V, and MTHFR
genotype. (a) Wild-type reaction for prothrombin and factor V.
(b) Mutant reaction for prothrombin and factor V. In (a and b), lane 1
is a 100 bp ladder, lanes 2 through 5 are experimental patient
samples (lane 3 is a patient heterozygous for the prothrombin
G20210A mutation), lane 6 is a positive control for prothrombin
G20210A, lane 7 is a positive control for factor V Leiden, and lane 8
is a no DNA negative control. (c) Wild-type reaction for MTHFR.
(d) Mutant reaction for MTHFR. In (c and d), lane 1 is a 100 bp ladder,
lanes 2 and 3 are experimental patient samples, and lane 4 is no DNA
control. Note there is an extra band in both the ( c and d) gels which
represents primer dimers.
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